Park Avenue Securities LLC Has $2.43 Million Stake in Bristol Myers Squibb Company $BMY

Park Avenue Securities LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 47.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 53,831 shares of the biopharmaceutical company’s stock after purchasing an additional 17,266 shares during the quarter. Park Avenue Securities LLC’s holdings in Bristol Myers Squibb were worth $2,428,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS lifted its holdings in shares of Bristol Myers Squibb by 6.6% during the third quarter. KLP Kapitalforvaltning AS now owns 1,527,558 shares of the biopharmaceutical company’s stock worth $68,893,000 after buying an additional 94,500 shares in the last quarter. Cerity Partners LLC increased its position in Bristol Myers Squibb by 9.2% during the third quarter. Cerity Partners LLC now owns 942,270 shares of the biopharmaceutical company’s stock worth $42,496,000 after acquiring an additional 79,647 shares during the period. Tilson Financial Group Inc. raised its stake in Bristol Myers Squibb by 4.2% in the 3rd quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 259 shares in the last quarter. Mccarter Private Wealth Services LLC boosted its holdings in Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 235 shares during the period. Finally, CoreCap Advisors LLC grew its position in shares of Bristol Myers Squibb by 14.8% during the 3rd quarter. CoreCap Advisors LLC now owns 20,309 shares of the biopharmaceutical company’s stock worth $916,000 after purchasing an additional 2,613 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price target on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Morgan Stanley reaffirmed an “underweight” rating and issued a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the stock from $46.00 to $65.00 in a report on Wednesday. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Six equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $56.62.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $55.92 on Friday. The stock has a fifty day moving average of $50.93 and a 200-day moving average of $47.80. The stock has a market capitalization of $113.84 billion, a P/E ratio of 18.89, a price-to-earnings-growth ratio of 9.29 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 85.14%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.